Choline alfoscerate
ApprovedSmall molecule
Chong Kun Dang PharmaceuticalCholine alfoscerate is one of 47 small molecule programs targeting Cognitive impairment. It is currently in Approved.
2
Indications
6
Total Trials
1
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
279 competitors in Cognitive Impairment
#DrugCompanyPhaseTrials
1Actos
TakedaPhase 3
Farxiga
AstraZenecaPhase 3
Xarelto
WWim Janssens
Phase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
Provigil
NNuvo Research GmbH
Phase 3
Viagra
VViatris Specialty LLC
Phase 3
Donepezil Hydrochloride
EisaiPhase 3
Statins
SanofiPhase 3
Nicorette
PfizerPhase 2
Galantamine Hydrobromide
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cognitive impairment3 trials
Cognitive Function1 trial
Injury1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Choline alfoscerate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details